Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23 2020 - 4:05PM
Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a
pharmaceutical technology company, today announced that Robert F.
Apple, President and Chief Executive Officer has participated in a
fireside chat presentation and will host investor meetings at the
Piper Sandler 32nd Annual Virtual Healthcare Conference being held
on December 1-3, 2020.
The pre-recorded webcast of the fireside chat
will be available under the “For Investors” section of the Antares
Pharma website at www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a pharmaceutical
technology company focused primarily on the development and
commercialization of self-administered injectable pharmaceutical
products using advanced drug delivery auto injector technology. The
Company has a portfolio of proprietary and partnered commercial
products with several product candidates in various stages of
development, as well as significant strategic alliances with
industry leading pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis),
Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).
Antares Pharma’s FDA-approved products include XYOSTED®
(testosterone enanthate) injection, OTREXUP® (methotrexate)
injection for subcutaneous use and Sumatriptan Injection USP, which
is distributed by Teva. The Company also markets NOCDURNA®
(desmopressin acetate) in the U.S., which was licensed from Ferring
Pharmaceuticals.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe
harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are subject to certain risks and uncertainties that can
cause actual results to differ materially from those described.
Factors that may cause such differences include, but are not
limited to: the Company’s ability to achieve the 2020 full-year
revenue guidance; the uncertainty regarding the
duration, scope and severity of the COVID-19 pandemic and the
mitigation measures and other restrictions implemented in response
to the same and the impact on
demand for our products, new patients and
prescriptions, future revenue, product supply, and
our overall business, operating results and financial
condition; successful commercialization of
NOCDURNA® in the United States
and market acceptance and future revenue from the
same: commercial success of
XYOSTED® and future
revenue from the same; market acceptance of Teva’s
generic epinephrine auto-injector product and future revenue from
the same; whether the FDA will withdraw marketing
approval for Covis’
Makena® subcutaneous auto
injector following the recent FDA letter seeking withdrawal,
whether Covis will be granted an
appeal hearing and if granted, whether
Covis will be successful and
future prescriptions, market acceptance and revenue from
the same; Teva’s ability to successfully commercialize
VIBEX® Sumatriptan Injection USP
and the amount of revenue from the same; future prescriptions and
sales of OTREXUP®; Teva’s ability
to successfully commercialize generic teriparatide in 11 countries
in Europe, Canada and Israel and future revenue from the same,
successful development including the timing and results of the
clinical bridging and Phase 3 clinical trial of
the drug device combination product for
Selatogrel with Idorsia Pharmaceuticals
and FDA and global regulatory approvals and future revenue from the
same; FDA approval of Teva’s pending ANDA for generic
Forteo and future revenue from the same;
the timing and results of the Company’s or its partners’ research
projects or clinical trials of product candidates in development
including Pfizer’s undisclosed development product; actions by the
FDA or other regulatory agencies with respect to the Company’s
products or product candidates of its partners; continued growth in
product, development, licensing and royalty revenue; the Company’s
ability to meet loan extension and interest only payment milestones
and the ability to repay the debt obligation to Hercules Capital;
the Company’s ability to obtain financial and other resources for
its research, development, clinical, and commercial activities and
other statements regarding matters that are not historical facts,
and involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:Tram BuiVice President,
Corporate Communications and Investor
Relations609-359-3016tbui@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2023 to Sep 2024